Literature DB >> 17895470

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Larry V Rubinstein, Janet E Dancey, Edward L Korn, Malcolm A Smith, John J Wright.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17895470     DOI： 10.1093/jnci/djm167

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Resampling phase III data to assess phase II trial designs and endpoints.

Authors:  Manish R Sharma; Theodore G Karrison; Yuyan Jin; Robert R Bies; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

2.  The statistics of phase 0 trials.

Authors:  Larry V Rubinstein; Seth M Steinberg; Shivaani Kummar; Robert Kinders; Ralph E Parchment; Anthony J Murgo; Joseph E Tomaszewski; James H Doroshow
Journal:  Stat Med       Date:  2010-05-10       Impact factor: 2.373

3.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

4.  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Authors:  Michael L Maitland; Matthew R Levine; Mario E Lacouture; Kristen E Wroblewski; Christine H Chung; Ilyssa O Gordon; Livia Szeto; Gail Ratko; Keyoumars Soltani; Mark F Kozloff; Philip C Hoffman; Ravi Salgia; David P Carbone; Theodore G Karrison; Everett E Vokes
Journal:  BMC Cancer       Date:  2014-01-04       Impact factor: 4.430

5.  Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Authors:  Michael L Maitland; Julia Wilkerson; Sanja Karovic; Binsheng Zhao; Jessica Flynn; Mengxi Zhou; Patrick Hilden; Firas S Ahmed; Laurent Dercle; Chaya S Moskowitz; Ying Tang; Dana E Connors; Stacey J Adam; Gary Kelloff; Mithat Gonen; Tito Fojo; Lawrence H Schwartz; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.